|Positive WB detected in||human heart tissue, human liver tissue, L02 cells|
|Positive IHC detected in||human liver tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HepG2 cells|
|Positive FC detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
13560-1-AP targets BST2 in WB, IHC, IF, FC, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Immunogen||BST2 fusion protein Ag4430|
|Full Name||bone marrow stromal cell antigen 2|
|Calculated molecular weight||180 aa, 20 kDa|
|Observed molecular weight||30-36 kDa|
|GenBank accession number||BC033873|
|Gene ID (NCBI)||684|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
BST2, also named as CD317 and Tetherin, belongs to the tetherin family. It may be involved in the sorting of secreted proteins and it is involved in pre-B-cell growth. BST2 is an antiretroviral defense protein, that blocks release of retrovirus from the cell surface. Depleted unpon HIV-1 infection by viral VPU protein through 20S proteasome degradation. Depleted upon infection by human Kaposi's sarcoma-associated herpesvirus (KSHV) through ubiquitination and subsequent degradation. BST2 may play a role in B-cell activation in rheumatoid arthritis. It is recently identified interferon-induced cellular proteins that restrict infections by retroviruses and filoviruses and of influenza virus and flaviviruses, respectively. BST2 is a plasma membrane proteins, tetherin inhibits virion particle release from infected cells. BST2 is effective against retroviruses and flavoviruses whilst IFITMs disrupt influenza and flavivirus infection. Observed MW of BST2 is 30-36 kDa (PMID: 19196977; 21237475).
|Product Specific Protocols|
|WB protocol for BST2 antibody 13560-1-AP||Download protocol|
|IHC protocol for BST2 antibody 13560-1-AP||Download protocol|
|IF protocol for BST2 antibody 13560-1-AP||Download protocol|
|FC protocol for BST2 antibody 13560-1-AP||Download protocol|
|Click here to view our Standard Protocols|
BST2 promotes cell proliferation, migration and induces NF-κB activation in gastric cancer.
MicroRNA-760 inhibits cell viability and migration through down-regulating BST2 in gastric cancer.
Biochem Biophys Res Commun
BST2/tetherin inhibits dengue virus release from human hepatoma cells.
BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells.
Preadaptation of SIVsmm facilitated Env-mediated counteraction of human tetherin by HIV-2.